BC Combo showed an earlier onset of appearance (Early t 0.5max ) and higher early PK exposure in the first hour compared with LMx and G+L ( Fig. 1a & Table 2 ).
o
After reaching t max , PK-profiles declined more rapidly with BC Combo than with LMx with lower exposure from 2 to 6 hours indicating a faster transition from prandial to basal insulin exposure.
o Total exposure over 6 hours was lower with BC Combo than with LMx or G+L, but as expected PKexposure was ongoing with all three insulins at the end of the test meal period.
Pharmacodynamics o BG profiles correlated well with PK profiles. o BC Combo significantly reduced mean maximum postprandial blood glucose concentrations and the postprandial glucose excursions over the first 2 hours compared with LMx and G+L (Fig. 1b & o Male or female subjects aged 18 to 70 years (both inclusive) with T2DM ≥12 months, HbA1c between 7 and 9.5% (both inclusive), a body mass index (BMI) between 20 and 40 kg/m² (both inclusive), treated with once daily injections with insulin glargine U-100 or insulin glargine U-300 for at least 3 months prior to screening with a total insulin dose <1.2 U/kg/day and a dose of insulin glargine ≥0.2 U/kg/day were allowed to participate in the trial after having given written informed consent. Baseline characteristics of the study population o All subjects were white with 9 (23.1%) females and 30 (76.9%) males.
o The mean age was 60.8 ± 7.5 years (mean ± SD) with a diabetes duration of 13.4 ± 5.4 years. The BMI was of 31.4 ± 4.1 kg/m². HbA1c at screening was 8.0 ± 0.64%.
o All subjects used once daily injection with insulin glargine, either alone or in combination with insulin lispro (n=9) or insulin glulisine (n=8). 
